Image

The Study of Olaparib in Newly Diagnosed mCRPC Patients With HRR Gene Mutation

Recruiting
18 years of age
Male
Phase 2

Powered by AI

Overview

This is a multi-center, single-arm, prospective study to assess the efficacy and safety of Olaparib in men with newly diagnosed metastatic castration-resistant prostate cancer (mCRPC) who carried homologous recombination repair (HRR) gene mutations and have progressed after treatment with novel endocrine agents (NHA) in the metastatic castration-sensitive prostate cancer or non-metastatic castration-resistant prostate cancer.

A total of 30 newly diagnosed mCRPC subjects with radiologically evaluable disease at baseline who have progressed on prior NHA and carry HRR gene mutations that meet the criteria will be included in the study. Eligible subjects will receive a treatment regimen of oral Olaparib tablets 300 mg twice daily until disease progression or intolerance. During the treatment and follow-up periods, all subjects will have regular visits to assess the efficacy and safety of Olaparib. Data on objective radiographic response (ORR), prostate-specific antigen response (PSA response), radiographic progression-free survival (rPFS), and time to prostate-specific antigen progression (TTPP) will be collected during the study.

Eligibility

Inclusion Criteria:

        For inclusion in the study, subjects should fulfil the following criteria based on local
        regulations:
          1. Provision of informed consent prior to any study specific procedures.
          2. Adult male patients (age≥18 years old).
          3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
          4. Histologically confirmed adenocarcinoma of the prostate.
          5. Subjects must have previously received NHA (e.g., abiraterone acetate and/or
             enzalutamide) for mHSPC or nmCRPC and have disease progression to mCRPC. Disease
             progression was determined by the local investigator based on the diagnostic criteria
             for mCRPC (CRPC diagnostic criteria: testosterone maintained at castrate levels
             (testosterone levels less than 50 ng/dL or 1.7 nmol/L) while meeting at least one of
             the following criteria: A. biochemical progression: three consecutive rising PSA with
             an interval of at least one week between the two tests, more than 50% increase from
             the nadir, and PSA > 2 ng/mL; B. radiographic progression: new lesions: two or more
             new bone lesions on bone scan or one soft tissue lesion meeting the RECIST criteria.
             Symptomatic progression alone is not sufficient to diagnose CRPC. Established
             radiographic evidence of metastatic disease in addition to CRPC to confirm the
             diagnosis of mCRPC).
          6. The subject had a serum testosterone level ≤ 50 ng/dL (≤ 1.75 nmol/L) before
             enrollment.
          7. Patients who have not undergone previous surgery must be taking and voluntarily
             continue taking LHRH analogues (agonists or antagonists) throughout the study
             treatment period.
          8. Subjects must have at least 1 measurable lesion at baseline (according to RECIST 1.1
             criteria: At least one lesion, not previously irradiated, that can be accurately
             measured at baseline as ≥ 10 mm in the longest diameter (except lymph nodes which must
             have short axis ≥ 15 mm) with computed tomography (CT) or magnetic resonance imaging
             (MRI) and which is suitable for accurate repeated measurements).
          9. Subjects must have at least 1 qualifying HRR gene mutation in tumor tissue and/or
             plasma ct-DNA confirmed by central lab (Glorious Med, shanghai, China)
               -  Archival or new biopsies are acceptable.
               -  Qualifying HRR gene mutations (deleterious or suspected deleterious gene
                  alterations) are BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL,
                  PALB2, RAD51B, RAD 51C, RAD51D and RAD54L mutations confirmed by the central lab.
         10. Subjects must have normal organ and bone marrow function at baseline, as defined
             below:
               -  Hemoglobin ≥ 10.0 g/dL without previous transfusion.
               -  Absolute neutrophil count ≥ 1.5 × 10^9/L.
               -  Platelet count ≥ 100 × 10^9/L.
               -  Total bilirubin ≤ 1.5 × the upper limit of normal (ULN) specified.
               -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase/alanine
                  aminotransferase (ALT) serum glutamic pyruvic transaminase) ≤ 2.5 × the specified
                  ULN, unless liver metastases are present, in which case it must be ≤ 5 × ULN.
               -  Estimated creatinine clearance ≥ 51 mL/min (estimated creatinine clearance = [140
                  - age (years)] × weight (kg)/serum creatinine (mg/dL)/72).
         11. Male subject has been surgically sterilized or uses an acceptable method of
             contraception (defined as a barrier method with spermicide) to prevent pregnancy
             during the duration of the study and for 12 weeks after the dose of prednisone.
         12. Subjects must have a life expectancy ≥ 16 weeks.
         13. The subjects must volunteer and be capable of complying with the protocol for the
             duration of the study, including receiving treatment, attending scheduled visits and
             hospital examinations.
        Exclusion Criteria:
        Subjects should not enter the study if any of the following exclusion criteria are
        fulfilled:
          1. Involvement in the planning and/or conduct of the study (applies to both Investigator
             staff and/or staff at the study site) .
          2. Previous enrolment in the present study.
          3. Subjects participated in another clinical study with a drug or plan to participate in
             another interventional clinical study within 30 days prior to enrollment.
          4. Prior treatment with any PARP inhibitor including Olaparib.
          5. Prior chemotherapy with any DNA-damaging cytotoxic agent unless used to treat
             non-prostate cancer and the last dose was at least 5 years prior to enrollment in this
             study. For example: Patients previously treated with mitoxantrone or platinum-based
             chemotherapy for prostate cancer are excluded.
          6. Other malignancies within the last 5 years.
          7. Uncontrolled or underlying cardiac disease on resting electrocardiogram (eg, but not
             limited to: unstable ischemia, uncontrolled symptomatic arrhythmia, congestive heart
             failure, QT prolongation > 500 ms with Fridericia correction, congenital long QT
             syndrome).
          8. The subject had received any systemic anticancer therapy (except radiotherapy) 3 weeks
             prior to study treatment.
             Medications used to maintain castrate status were permitted as described in Inclusion
             Criteria 7. Drugs such as 5-α reductase inhibitors (finasteride, dutasteride),
             estrogen compounds, and megestrol are considered as anticancer drugs and are
             prohibited at least 3 weeks before study treatment.
             Treatment of bone metastases with denosumab or bisphosphonates such as zoledronic acid
             is allowed.
          9. Concomitant use of known strong CYP3A inhibitors (e.g. itraconazole, telithromycin,
             clarithromycin, ritonavir, or carbidetex-boosted protease inhibitors, indinavir,
             saquinavir, nelfinavir, baprevir, teicoplanavir) or moderate CYP3A inhibitors (e.g.
             ciprofloxacin, erythromycin, sulfadiazine, fluconazole, vilapamil) requires a 2-week
             washout period prior to initiation of Olaparib therapy.
         10. Concomitant use of strong CYP3A inducers (e.g. phenobarbital, empagliflozin,
             phenytoin, rifampin, rifampin, rifampin, rifapentine, carbamazepine, nevirapine, and
             Forsythia leaf) or moderate CYP3A inducers (e.g. bosentan, efavirenz, modafinil). If
             co-administered with phenobarbital, a 5-week washout period is required before the
             start of Olaparib therapy and a 3-week washout period is required when co-administered
             with other drugs.
         11. Subjects with major surgery within 2 weeks of starting study treatment and patients
             must have recovered from any effects of any major surgery.
         12. Subjects with previous allogenic bone marrow transplant or double umbilical cord blood
             transplantation (dUCBT).
         13. Long-term toxicity (CTCAE > grade 2) due to prior cancer therapy, excluding toxicity
             due to alopecia or use of LHRH agonists or antagonists.
         14. Subjects with myelodysplastic syndrome/acute myeloid leukaemia or with features
             suggestive of MDS/AML
         15. Subjects with known brain metastases (confirmation of absence of brain metastases by
             scan is not required).
         16. Subjects with spinal cord compression unless considered to have received definitive
             treatment for this and evidence of clinically stable disease for 4 weeks.
         17. Subjects who are unable to swallow oral medication and/or have a gastrointestinal
             disorder that would interfere with absorption of the study drug.
         18. Subjects with known hypersensitivity to Olaparib or any of the excipients of this
             product.
         19. Immunocompromised subjects, such as those with positive human immunodeficiency virus
             (HIV) serology.
         20. Subjects with known active hepatitis (e.g. hepatitis B or C).
         21. The subject has a serious, uncontrolled medical condition or non-malignant systemic
             disease, or an uncontrolled active infection. ( For example, but not limited to:
             uncontrolled arrhythmia, 12 myocardial infarction, uncontrolled seizures, extensive
             interstitial lung disease in both lungs, or psychiatric disease that would preclude
             informed consent.)-

Study details

Prostate Cancer, Prostate Carcinoma, Metastatic Castration-resistant Prostate Cancer

NCT05262608

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

25 January 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.